NWNelson B. Watts

Nelson B. Watts

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nelson B. Watts has a total of 148 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Standard Techniques of Bone Mass Measurement in Adults

    by E. Michael Lewiecki, Paul D. Miller, Nelson B. Watts


  • Recombinant human parathyroid hormone (rhPTH[1-84], parathyroid hormone rDNA) improves hypercalciuria in patients with hypoparathyroidism: 3-year analysis from RACE study

    by Bart L Clarke, Tamara J Vokes, John P Bilezikian, Henry G Bone, Douglas S Denham, Hak-Myung Lee, Michael A Levine, Michael Mannstadt, Munro Peacock, Jeffrey G Rothman, et al.

    Hypoparathyroidism (HPT) is characterised by hypocalcaemia and impaired renal phosphate excretion and calcium conservation. Oral calcium supplements and calcitriol can improve serum calcium levels but lack the physiologic effects of PTH on renal reabsorption of calcium. RACE is an ongoing open-label study evaluating the long-term safety of recombinant human parathyroid hormone 1-84 (rhPTH[1-84], parathyroid hormone rDNA) in adults with HPT (NCT01297309). In this interim analysis, we report the 3-year treatment effect with 25–100 μg/day rhPTH(1-84) on 24-h urinary calcium levels, with or without thiazide diuretics. All data are presented as mean (SD). The study cohort comprised 49 patients enrolled at 12 USA centres; 38 (78%) completed 36 months of rhPTH(1-84) treatment. Baseline demographics were as follows: 82% women, age 48 (9.8) years, HPT duration of 16 (12.5) years, 100% taking prescribed calcium supplements and calcitriol. In response to rhPTH(1-84), albumin-corrected serum calcium remained within the target range over the 3 years; 2.1 (0.17) mmol/l at baseline (i.e., start of rhPTH[1-84], n=49) and Month 36 (n=36). Treatment with rhPTH(1-84) also led to a reduction in urinary calcium, from baseline 8.9 (5.0) mmol/24 h to 6.5 (2.8) mmol/24 h (n=35; Pn=12/17). Treatment with rhPTH(1-84) improved calcium–phosphate product from baseline 3.4 (0.5) mmol2/l2 (n=49) to 2.9 (0.5) mmol2/l2 (n=36) (Pn=41) and 115.7 (47.3) ml/min (n=36) at Month 36 (P<0.0772). Over 3 years, rhPTH(1-84) maintained target levels of serum calcium and reduced urinary calcium to normal levels in HPT patients. More information is needed to understand the timing of the beneficial effect on urinary calcium excretion.

  • Secondary Osteoporosis

    by Dima L. Diab, Nelson B. Watts

    There are numerous causes of secondary osteoporosis including endocrine disorders, nutritional deficiencies, and other miscellaneous conditions and medications. It is essential to identify and address these factors to appropriately manage patients with osteoporosis. Failure to do so may result in further bone loss despite pharmacologic intervention for osteoporosis. The following diagnostic studies should be considered initially: complete blood count, complete metabolic panel, 25-hydroxyvitamin D level, testosterone level in men, and 24-hour urinary calcium, sodium, and creatinine. Further testing may be performed in selected patients depending on the clinical picture and results of the initial workup.


  • Disease-specific perception of fracture risk and incident fracture rates among postmenopausal women: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)

    by Celia Gregson, Elaine Dennison, Juliet Compston, Silvano Adami, Jonathan Adachi, Frederick Anderson, Steven Boonen, Roland Chapurlat, Adolfo Diez-Perez, Susan Greenspan, et al.

    Patients with improved health understanding have greater autonomy over, and motivation towards, health-related lifestyles. We compared self-perceived fracture risk and 3-year incident fracture rates in postmenopausal women for a range of co-morbid diseases using data from the Global Longitudinal study of Osteoporosis in Women (GLOW). GLOW is an international cohort study involving 723 physician practices across 10 countries in Europe, North America, Australasia. 60 393 women aged ≥55 years completed baseline questionnaires detailing medical history, including co-morbidities, fractures and self-perceived fracture risk. Annual follow-up determined self-reported incident fractures. In total, 2945/43 832 (6.7%) sustained an incident fracture over 3 years. All co-morbidities were strongly associated with increased fracture rates, particularly Parkinson’s disease (PD) (hazard ratio (HR) 95% CI; 3.89 (2.78, 5.44)), multiple sclerosis (MS) 2.70 (1.90, 3.83), cerebrovascular events 2.02 (1.67, 2.46), and rheumatoid arthritis 2.15 (1.53, 3.04), all P<0.001). Most individuals perceived their own fracture risk to be similar to (46%) or lower than (36%) women of the same age. Increased self-perceived fracture risk was strongly associated with incident fracture rates. However, only 29% of women who experienced a fracture had perceived their risk as increased. Under-appreciation of fracture risk occurred for all co-morbidities, particularly for women with neurological disease, in whom women with self-perceived low fracture risk had a fracture HR of 2.39 (1.74, 3.29) compared with women without co-morbidities. Our results suggest postmenopausal women with co-morbidities known to be associated with increased fracture rates tend to under-appreciate their risk, especially in the context of neurological diseases, where fracture rates are highest. Our findings have important implications for health education particularly among women with neurological disease and support updating of relevant guidelines.

  • Nanomaterial-Based Electroanalytical Biosensors for Cancer and Bone Disease

    by Yeoheung Yun, Boyce Collins, Zhongyun Dong, Christen Renken, Mark Schulz, Amit Bhattacharya, Nelson Watts, Yongseok Jang, Devdas Pai, Jag Sankar

  • Open Access

    Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

    by N. B. Watts, C. Roux, J. F. Modlin, J. P. Brown, A. Daniels, S. Jackson, S. Smith, D. J. Zack, L. Zhou, A. Grauer, et al.

    Summary Serious adverse events of infections that occurred in subjects receiving denosumab or placebo in the Fracture Reduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) study were examined in detail. Serious adverse events of infections in denosumab subjects had heterogeneous etiology, with no clear clinical pattern to suggest a relationship to time or duration of exposure to denosumab. Introduction Denosumab reduces the risk for new vertebral, hip, and nonvertebral fractures compared with placebo. In the pivotal phase 3 fracture trial (FREEDOM), the overall safety profile and incidence of adverse events including adverse events of infections were similar between groups. Serious adverse events of erysipelas and cellulitis were more frequent in denosumab-treated subjects. In this report, we further evaluate the details of infectious events in FREEDOM to better understand if RANKL inhibition with denosumab influences infection risk. Methods FREEDOM was an international multicenter, randomized, double-blind, placebo-controlled study in postmenopausal women with osteoporosis randomly assigned to receive placebo (n = 3,906) or denosumab 60 mg every 6 months (n = 3,902). The incidence of adverse events and serious adverse events categorized within the Medical Dictionary for Regulatory Activities system organ class, “Infections and Infestations,” was compared between the placebo and denosumab groups by body systems and preferred terms. The temporal relationship between occurrence of serious adverse events of infections of interest and administration of denosumab was explored. Results Serious adverse events of infections involving the gastrointestinal system, renal and urinary system, ear, and endocarditis were numerically higher in the denosumab group compared with placebo, but the number of events was small. No relationship was observed between serious adverse events of infections and timing of administration or duration of exposure to denosumab. Conclusions Serious adverse events of infections that occurred with denosumab treatment had heterogeneous etiology, with no clear clinical pattern to suggest a relationship to time or duration of exposure to denosumab.


  • The Fracture Risk Assessment Tool (FRAX ® ): Applications in Clinical Practice

    by Nelson B. Watts

    Osteoporosis is a serious health concern affecting millions of Americans, with many patients going undiagnosed and untreated. Fractures due to osteoporosis and fracture-related complications are the most clinically relevant and costly consequences of this disorder. The Fracture Risk Assessment Tool (FRAX®), released by the World Health Organization (WHO) in February 2008, is a major achievement in helping determine which patients may be candidates for pharmacological therapy for osteoporosis. This Web-based algorithm, which has been incorporated into some dual x-ray absorptiometry (DXA) reporting software, calculates the 10-year probability of major osteoporotic fracture (clinical vertebral, hip, forearm, or humerus) and the 10-year probability of hip fracture in men and women based on easily obtained clinical risk factors and bone mineral density (BMD) of the femoral neck (optional). The National Osteoporosis Foundation updated its U.S. guidelines in February 2008 to incorporate FRAX and recommends that all postmenopausal women and men aged ≥50 years with a hip or vertebral fracture, a T-score ≤-2.5 at the femoral neck or spine (excluding secondary causes), or low bone mass (T-score between -1.0 and -2.5) and a 10-year probability of hip fracture ≥3% or of major osteoporosis-related fracture ≥20% (based on FRAX) should be considered candidates for drug therapy. Despite its demonstrated clinical utility, FRAX has limitations and should not be used in all situations. Acceptance and clinical use of FRAX may help identify men and women at increased risk for osteoporotic fracture, but implementing the tool into clinical practice may be a challenge for busy physicians.